Ditan
| Ditan | |
|---|---|
| Drug class | |
 Lasmiditan | |
| Class identifiers | |
| Use | Migraine |
| Biological target | 5-HT1F receptor |
| Legal status | |
| In Wikidata | |
Ditans[citation needed] are a class of abortive medication for the treatment of migraines.[1]
Ditans selectively bind to the 5-HT1F receptor subtype. A number of triptans have been shown to act on this subtype as well, but only after their affinity for 5-HT1B and 5-HT1D has been made responsible for their anti-migraine activity. The lack of affinity for these receptors might result in fewer side effects related to vasoconstriction compared to triptans in susceptible patients, such as those with ischemic heart disease, Raynaud's phenomenon or after a myocardial infarction.[2] A 1998 review has found such side effects to rarely occur in most patients taking triptans.[3][4] The first drug in this class is Eli Lilly's experimental drug lasmiditan. Alniditan is another example.[citation needed]
References
- ^ http://adisinsight.springer.com/drugs/800028519
- ^ "Molecule of the Month July 2010: Lasmiditan hydrochloride". Prous Science. Retrieved 2011-08-03.
- ^ Dahlöf, CG; Mathew, N (1998). "Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?". Cephalalgia : an international journal of headache. 18 (8): 539–45. doi:10.1046/j.1468-2982.1998.1808539.x. PMID 9827245.
- ^ Mutschler, Ernst; Geisslinger, Gerd; Kroemer, Heyo K.; Schäfer-Korting, Monika. Arzneimittelwirkungen. Wissenschaftliche Verlagsgesellschaft.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |